You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

67 Results
Regimen
Intent: Adjuvant
Funding:
ODB - General Benefit
    anastrozole
Apr 2024
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Jan 2024
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours, 
Sarcoma, 
GIST
Intent: Adjuvant
Funding:
ODB - General Benefit
    iMAtinib - Refer to listed Health Canada indications for generic imatinib formulations. Patients must meet generic substitution policies for access to Gleevec®
Oct 2024
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Adjuvant, Curative
May 2019
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Adjuvant, Curative
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    capecitabine
Jul 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Gynecologic, 
Uterine Sarcoma, 
Sarcoma, 
Uterine
Intent: Adjuvant, Palliative
May 2019
Regimen
Cancer Type:
Lung, 
Non-Small Cell, 
Small Cell
Intent: Neoadjuvant, Adjuvant, Curative, Palliative
May 2019
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Intent: Neoadjuvant, Adjuvant, Palliative
Jan 2024
Regimen
Cancer Type:
Sarcoma, 
Ewing's, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
Jun 2019

Pages